Full-Time

Lead Counsel

Global Data Digital & Technology

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm focused on R&D

Compensation Overview

$208.2k - $327.1k/yr

+ Short-term Incentives + Long-term Incentives

Senior

Boston, MA, USA

This position is currently classified as 'hybrid' in accordance with Takeda's Hybrid and Remote Work policy.

Category
Legal
Risk & Compliance
Legal & Compliance
Requirements
  • Juris Doctor (JD) degree from an accredited law school and bar membership in at least one jurisdiction
  • At least 8+ years of relevant technology law experience in a law firm and/or in-house legal department in a technology or healthcare company
  • Proven experience in counseling on software/SaaS and technology transaction matters
  • Strong understanding of technology and its legal and ethical implications, knowledge of industry standards and best practices in cybersecurity and data privacy
  • Strong understanding of data protection laws, cybersecurity regulations, experience in incident response
  • Self-motivated, proactive, and ability to work collaboratively with cross-functional teams to solve problems, drive decisions and exercise good judgement
  • Superior written and verbal communication skills in policy drafting and to convey complex legal & business concepts to business stakeholders
  • Ability to influence others without direct authority on novel matters related to our industry
Responsibilities
  • Building a trusted advisor relationship with senior managers and leaders within the Global Data Digital & Technology Function supporting its goals and objectives
  • Advising on relevant cybersecurity laws and regulations, keeping up to date with prospective changes and industry technology trends and proactively educating relevant stakeholders and ensuring business is prepared to respond
  • Work closely with business and cross functional stakeholders to ensure operational policies align with legal requirements, including new and emerging laws and regulations, and support policy development and implementation
  • Advise on AI matters, including internal governance, risk assessments and regulatory review, relating to AI development and deployment within the enterprise
  • Provide product counselling, and engage with cross functional partners to advise on IP, software, licensing and other product related legal matters
  • Project management and the furtherance of process improvement in legal support to GDD&T
  • Support GDD&T on the legal aspects of its Governance, Risk and Compliance program
Desired Qualifications
  • Certification in cybersecurity (e.g., CISSP, CIPP) desirable
  • Experience in leading, managing and inspiring virtual teams or practice groups is a plus

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate and provide life-changing therapies while ensuring that patient needs are prioritized.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's focus on personalized medicine can increase treatment efficacy and patient satisfaction.
  • Expansion in Southeast Asia offers opportunities for increased market presence and revenue growth.
  • Collaborations with tech companies can accelerate R&D processes and reduce costs.

What critics are saying

  • Data breach could lead to financial and reputational damage for Takeda.
  • Antitrust litigation with Meijer may result in financial penalties or business practice changes.
  • High financial commitments in partnerships could strain resources if outcomes are not achieved.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and R&D efforts.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 product launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

CyberNews
Apr 15th, 2025
Hackers want $75,000 for data allegedly stolen from Takeda

A new account on an illicit forum bearing the moniker "beltway" claims that in April 2025, it exported around two million rows of user information from Takeda.com.

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.